Page 55 - Read Online

Kepka. J Cancer Metastasis Treat 2019;5:53 I http://dx.doi.org/10.20517/2394-4722.2018.114 Page 11 of 11

42. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic
radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295:2483-91.
43. Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery
or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011;29:134-41.
44. Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, et al. Stereotactic radiosurgery for patients with multiple brain metastases
(JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 2014;15:387-95.
45. Wolfson AH, Bae K, Komaki R, Meyers C, Movsas B, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology
Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and
quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;81:77-84.
46. Socha J, Kepka L. Prophylactic cranial irradiation for small-cell lung cancer: how, when and for whom? Expert Rev Anticancer Ther
2012;12:505-17.
47. Gondi V, Pugh SL, Tome WA, Caine C, Corn B, et al. Preservation of memory with conformal avoidance of the hippocampal neural
stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG0933): a phase II multi-institutional trial. J Clin
Oncol 2014;32:3810-6.
48. Gondi V, Deshmukh S, Brown PD, et al. Preservation of neurocognitive function (NCF) with conformal avoidance of the hippocampus
during whole-brain radiotherapy (HA-WBRT) for brain metastases: preliminary results of phase III trial NRG Oncology CC001. Int J
Radiat Oncol Biol Phys 2018;102:1607S.
49. Kundapur V, Ellchuk T, Ahmed S, Gondi V. Risk of hippocampal metastases in small cell lung cancer patients at presentation and after
cranial irradiation: a safety profile study for hippocampal sparing during prophylactic or therapeutic cranial irradiation. Int J Radiat
Oncol Biol Phys 2015;91:781-6.
50. Harth S, Abo-Madyan Y, Zheng L, Siebenlist K, Herskind C, et al. Estimation of intracranial failure risk following hippocampal-sparing
whole brain radiotherapy. Radiother Oncol 2013;109:152-8.
51. Redmond KJ, Hales RK, Anderson-Keightly H, Zhou XC, Kummerlowe M, et al. Prospective study of hippocampal-sparing prophylactic
cranial irradiation in limited-stage small cell lung cancer. Int J Radiat Oncol Biol Phys 2017;98:603-11.
52. Qu XM, Mishra MV, Bauman GS, Slotman B, Mehta M, et al. Cost-effectiveness of prophylactic cranial irradiation with hippocampal
avoidance in limited stage small cell lung cancer. Radiother Oncol 2017;122:411-5.
53. Rodriguez de Dios N, Counago F, Lopez JL, Calvo P, Murcia M, et al. Treatment design and rationale for a randomized trial of
prophylactic cranial irradiation with or without hippocampal avoidance for sclc: premer trial on behalf of the oncologic group for the
study of lung cancer/spanish radiation oncology group-radiation oncology clinical research group. Clin Lung Cancer 2018;19:e693-7.
54. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, et al. Memantine for the prevention of cognitive dysfunction in patients receiving
whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15:1429-37.
55. Wartena R, Brandsma D, Belderbos J. Are memantine, methylphenidate and donepezil effective in sparing cognitive functioning after
brain irradiation? J Cancer Metastasis Treat 2018;4:59.
56. Bernhardt D, Hommertgen A, Schmitt D, El Shafie R, Paul A, et al. Whole brain radiation therapy alone versus radiosurgery for patients
with 1-10 brain metastases from small cell lung cancer (ENCEPHALON Trial): study protocol for a randomized controlled trial. Trials
2018;19:388.
57. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, et al. First-line Atezolizumab plus chemotherapy in Extensive-Stage
Small-Cell Lung Cancer. N Engl J Med 2018;379:2220-9.